TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04434053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIETHKE M.blue®
Description: The programmable shunt will be adjusted through the MIETHKE M.blue® valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIETHKE proGAV 2.0® (with SA 2.0®)
Description: The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
Study: NCT02674763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN779
Study: NCT00433186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate 3000 mg each day
Study: NCT01235637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
Study: NCT02997007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive active tDCS over the angular gyrus on five consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive active tDCS over the angular gyrus on five consecutive days
Study: NCT02788760

Intervention type: DEVICE
Group type: OTHER
Intervention: Cervical collar (Miami J collar - Össur)
Description: The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment

Intervention type: DEVICE
Group type: OTHER
Intervention: Cervical collar (Miami J collar - Össur)
Description: The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
Study: NCT01470859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet CR
Description: tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
Study: NCT03659955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood applied to dry eye
Description: See previous description for the study arm.
Study: NCT03543189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
Study: NCT02997007

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham tDCS over the angular gyrus on five consecutive days
Study: NCT03543189

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Standard of care.
Study: NCT04117685

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.
Study: NCT01982578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 360 days of double blind treatment of placebo.
Study: NCT03979131

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab addition to perioperative chemotherapy in GC and GEJC
Description: Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
Study: NCT03049722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker
Study: NCT03227328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
Description: CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
Description: Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant
Study: NCT04210024

Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Empowerment Education Program
Description: Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
Study: NCT03643965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon
Description: Nefecon 16 mg for daily administration by mouth for 9 months.
Study: NCT05059665

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
Study: NCT02940119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi Radiance Medical®
Description: Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multi Radiance Medical®
Description: Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
Study: NCT03934619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dolores One
Description: Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
Study: NCT01816399

Intervention type: PROCEDURE
Intervention: Routine coronary angiography
Study: NCT03643965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules for daily administration by mouth for 9 months.
Study: NCT00459550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK933776
Description: Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK933776
Description: Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
Study: NCT02771327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP plus Gas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventimask plus gas
Study: NCT04117685

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.
Study: NCT04722393

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise training
Study: NCT01879826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aculaser applied to kidney points
Description: The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aculaser applied to sham points
Description: The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
Study: NCT01904279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
Study: NCT00096122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT04714255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trace Image and Coloring for Kids-Book (TICK-B)
Description: A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
Study: NCT02598726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piperine Extract (Standardized)
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01638767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptives, Oral
Description: 0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive, Vaginal ring
Description: etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
Study: NCT02947555

Intervention type: OTHER
Intervention: Non interventional

Intervention type: OTHER
Intervention: Non interventional

Intervention type: OTHER
Intervention: Non interventional

Intervention type: OTHER
Intervention: Non interventional
Study: NCT00096122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT01947686

Intervention type: DEVICE
Intervention: Robotically guided patellofemoral UKA isolated patellofemoral implants
Description: A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
Study: NCT01463982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratecan and Capecitabine
Description: Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14
Study: NCT01139606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration resistance training
Description: adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
Study: NCT04601350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
Description: remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
Study: NCT02505178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
Study: NCT03529812

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT-informed training
Description: Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT-informed training
Description: Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
Study: NCT03437512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: 20 minutes of 2mA anodal stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency training
Description: Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fluency training
Description: Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, current is ramped up and back down over 30 seconds.
Study: NCT02247531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
Study: NCT01423019

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advantra Z
Description: Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Advantra Z + Naringin + Hesperiden
Description: Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
Study: NCT04601350

Intervention type: DRUG
Group type: OTHER
Intervention: control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
Description: control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
Study: NCT04095624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Fusion Preoperative Opioid Taper
Description: Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-taper Control
Description: Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
Study: NCT00464113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL228
Description: 1-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL228
Description: 1-hour IV infusion
Study: NCT02875028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: 10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: 2ng/kg Lipopolysaccharide as a bolus infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: 2ng/kg Lipopolysaccharide as a bolus infusion
Study: NCT00959569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: esmolol (1-3 mg/kg) during cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normosaline (same ml of the study drug)
Study: NCT04983524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis
Description: resinous product of honeybees

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Gold standard control intracanal medicament
Study: NCT03095755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
Study: NCT01423019

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
Study: NCT02078726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: glucagon (hormone produced by the body)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: glucagon (hormone produced by the body)
Study: NCT02500836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine HCl 4% Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine HCl 10% Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Solution
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Study: NCT03594474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion
Description: using higher dose of IV lipids after birth
Study: NCT01145183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo daily dosing
Study: NCT02208167

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HXTC infusion

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HXTC infusion